You could earn truly passive income with these investments. Find out how much you'll make in a single year, depending on how ...

If the FDA deems Pfizer’s and Moderna’s updated vaccines “new” products, it’s extremely unlikely the doses would be ready for ...

Icon's balance sheet is sound, with its revenue cyclicality and operating leverage each possessing a medium rating. Icon has historically maintained a fairly conservative balance sheet, and it ended ...

The US Department of Health and Human Services said Thursday that it aims to accomplish within four years a scientific feat ...

Pfizer CEO Albert Bourla stated that uncertainty over Trump’s planned pharmaceutical tariffs is deterring new U.S.

The Trump administration's effort to impose new requirements on Novavax's COVID-19 vaccine is sowing uncertainty about other ...

Shares of Arvinas fell after the biotechnology company ended plans for two Phase 3 trials as part of its collaboration with Pfizer, and said that it would cut about a third of its workforce. The stock ...

Madison Realty Capital set a company high watermark with its $700 million financing package, which is being finalized.

Pfizer CEO Albert Bourla said Tuesday that uncertainty surrounding President Donald Trump’s proposed pharmaceutical tariffs is discouraging the company from making additional investments in U.S.

With attention focused on their recently approved drugs for transthyretin amyloid cardiomyopathy (ATTR-CM), there was a ...

When it comes to vaccination, the COVID-19 pandemic divided American society. President Donald Trump and his new Health and ...

Pfizer and Arvinas have axed two phase 3 trials from their estrogen receptor (ER) degrader R&D plan in the wake of mixed data ...